Literature DB >> 9291104

Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.

M P Heyes1, C Y Chen, E O Major, K Saito.   

Abstract

Substantial increases in the tryptophan-kynurenine pathway metabolites, l-kynurenine and the neurotoxin quinolinic acid, occur in human brain, blood and systemic tissues during immune activation. Studies in vitro have shown that not all human cells are capable of synthesizing quinolinate. To investigate further the mechanisms that limit l-kynurenine and quinolinate production, the activities of kynurenine pathway enzymes and the ability of different human cells to convert pathway intermediates into quinolinate were compared. Stimulation with interferon gamma substantially increased indoleamine 2,3-dioxygenase activity and L-kynurenine production in primary peripheral blood macrophages and fetal brains (astrocytes and neurons), as well as cell lines derived from macrophage/monocytes (THP-1), U373MG astrocytoma, SKHEP1 liver and lung (MRC-9). High activities of kynurenine 3-hydroxylase, kynureninase or 3-hydroxyanthranilate 3,4-dioxygenase were found in interferon-gamma-stimulated macrophages, THP-1 cells and SKHEP1 cells, and these cells made large amounts of quinolinate when supplied with L-tryptophan, L-kynurenine, 3-hydroxykynurenine or 3-hydroxyanthranilate. Quinolinate production by human fetal brain cultures and U373MG cells was restricted by the low activities of kynurenine 3-hydroxylase, kynureninase and 3-hydroxyanthranilate 3,4-dioxygenase, and only small amounts of quinolinate were synthesized when cultures were supplied with L-tryptophan or 3-hydroxyanthranilate. In MRC-9 cells, quinolinate was produced only from 3-hydroxykynurenine and 3-hydroxyanthranilate, consistent with their low kynurenine 3-hydroxylase activity. The results are consistent with the notion that indoleamine 2,3-dioxygenase is an important regulatory enzyme in the production of L-kynurenine and quinolinate. Kynurenine 3-hydroxylase and, in some cells, kynureninase and 3-hydroxyanthranilate 3,4-dioxygenase are important determinants of whether a cell can make quinolinate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291104      PMCID: PMC1218677          DOI: 10.1042/bj3260351

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  23 in total

Review 1.  Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects.

Authors:  J M Carlin; Y Ozaki; G I Byrne; R R Brown; E C Borden
Journal:  Experientia       Date:  1989-06-15

2.  Human microglia convert l-tryptophan into the neurotoxin quinolinic acid.

Authors:  M P Heyes; C L Achim; C A Wiley; E O Major; K Saito; S P Markey
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

3.  Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues.

Authors:  M P Heyes; P F Morrison
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

4.  A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.

Authors:  M P Heyes; K Saito; E O Major; S Milstien; S P Markey; J H Vickers
Journal:  Brain       Date:  1993-12       Impact factor: 13.501

5.  Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.

Authors:  D B Naritsin; K Saito; S P Markey; C Y Chen; M P Heyes
Journal:  J Neurochem       Date:  1995-11       Impact factor: 5.372

6.  Kynurenine 3-hydroxylase in brain: species activity differences and effect of gerbil cerebral ischemia.

Authors:  K Saito; B J Quearry; M Saito; T S Nowak; S P Markey; M P Heyes
Journal:  Arch Biochem Biophys       Date:  1993-11-15       Impact factor: 4.013

7.  4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells).

Authors:  K Saito; C Y Chen; M Masana; J S Crowley; S P Markey; M P Heyes
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

8.  The preferred route of kynurenine metabolism in the rat.

Authors:  D A Bender; G M McCreanor
Journal:  Biochim Biophys Acta       Date:  1982-07-16

9.  Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia.

Authors:  K Saito; T S Nowak; S P Markey; M P Heyes
Journal:  J Neurochem       Date:  1993-01       Impact factor: 5.372

10.  Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation.

Authors:  K Saito; T S Nowak; K Suyama; B J Quearry; M Saito; J S Crowley; S P Markey; M P Heyes
Journal:  J Neurochem       Date:  1993-12       Impact factor: 5.372

View more
  63 in total

1.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

2.  An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells.

Authors:  Joshua D Mezrich; John H Fechner; Xiaoji Zhang; Brian P Johnson; William J Burlingham; Christopher A Bradfield
Journal:  J Immunol       Date:  2010-08-18       Impact factor: 5.422

3.  Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.

Authors:  Omran Abu Aboud; Ching-Hsien Chen; William Senapedis; Erkan Baloglu; Christian Argueta; Robert H Weiss
Journal:  Mol Cancer Ther       Date:  2016-07-07       Impact factor: 6.261

4.  Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.

Authors:  K Rejdak; A Petzold; T Kocki; J Kurzepa; P Grieb; W A Turski; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2007-03-29       Impact factor: 3.575

5.  Maternal Inflammation Results in Altered Tryptophan Metabolism in Rabbit Placenta and Fetal Brain.

Authors:  Monica Williams; Zhi Zhang; Elizabeth Nance; Julia L Drewes; Wojciech G Lesniak; Sarabdeep Singh; Diane C Chugani; Kannan Rangaramanujam; David R Graham; Sujatha Kannan
Journal:  Dev Neurosci       Date:  2017-05-11       Impact factor: 2.984

6.  Regulation of indoleamine 2,3-dioxygenase expression in simian immunodeficiency virus-infected monkey brains.

Authors:  E M E Burudi; M Cecilia G Marcondes; Debbie D Watry; Michelle Zandonatti; Michael A Taffe; Howard S Fox
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 7.  [Immunology in schizophrenic disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-03       Impact factor: 1.214

8.  Mirtazapine inhibits tumor growth via immune response and serotonergic system.

Authors:  Chun-Kai Fang; Hong-Wen Chen; I-Tsang Chiang; Chia-Chieh Chen; Jyh-Fei Liao; Ton-Ping Su; Chieh-Yin Tung; Yosuke Uchitomi; Jeng-Jong Hwang
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

9.  Characterisation of the expression of NMDA receptors in human astrocytes.

Authors:  Ming-Chak Lee; Ka Ka Ting; Seray Adams; Bruce J Brew; Roger Chung; Gilles J Guillemin
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

10.  Antibiotic-mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy.

Authors:  Verena Eggers; Katja Fügener; Ortrud Vargas Hein; Hans Rommelspacher; Melvyn P Heyes; Wolfgang J Kox; Claudia D Spies
Journal:  Intensive Care Med       Date:  2004-04-27       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.